Two-weeks treatment with cannabidiol improves biophysical and behavioral deficits associated with experimental type-1 diabetes
| Autor: | Joice Maria da Cunha, Janaina Menezes Zanoveli, Yane Costa Chaves, Cristina A.J. Stern, Gisele de Oliveira Guaita, José Alexandre de Souza Crippa, Karina Genaro |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine Serotonin medicine.medical_specialty Elevated plus maze medicine.medical_treatment NEUROCIÊNCIAS Hippocampus Imipramine Diabetes Mellitus Experimental Norepinephrine 03 medical and health sciences 0302 clinical medicine Internal medicine Diabetes mellitus medicine Animals Cannabidiol Rats Wistar Type 1 diabetes Behavior Animal business.industry General Neuroscience Insulin Streptozotocin medicine.disease Disease Models Animal 030104 developmental biology Endocrinology business 030217 neurology & neurosurgery medicine.drug Behavioural despair test |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP |
| ISSN: | 0304-3940 |
| DOI: | 10.1016/j.neulet.2020.135020 |
| Popis: | The prevalence rates of depression and anxiety are at least two times higher in diabetic patients, increasing morbidity and mortality. Cannabidiol (CBD) has been identified as a therapeutic agent viable to treat diverse psychiatric disorders. Thus, this study aimed to investigate the effect of CBD treatment (once a day for 14 days starting two weeks after diabetes induction; at doses of 0, 3, 10 or 30 mg/kg, i.p.) on depression- and anxiety-like behaviors associated with experimental diabetes induced by streptozotocin (60 mg/kg; i.p.) in rats. Levels of plasma insulin, blood glucose, and weight gain were evaluated in all experimental groups, including a positive control group treated with imipramine. The rats were tested in the modified forced swimming test (mFST) and elevated plus maze (EPM) test. Besides, the levels of serotonin (5-HT), noradrenaline (NA) and dopamine (DA) in two emotion-related brain regions, the prefrontal cortex (PFC) and hippocampus (HIP) were evaluated using high-pressure liquid chromatography. Our results showed that CBD treatment (only at the higher dose of 30 mg/kg) reduced the exaggerated depressive- and anxiogenic-like behaviors of diabetic (DBT) rats, which may be associated with altered 5-HT, NA and/or DA levels observed in the PFC and HIP. Treatment with CBD (higher dose) also induced a significant increase in weight gain and the insulin levels (and consequently reduced glycemia) in DBT rats. The long-term CBD effects gave rise to novel therapeutic strategies to limit the physiological and neurobehavioral deficits in DBT rats. This approach provided evidence that CBD can be useful for treating psychiatry comorbidities in diabetic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect